Stay updated on IMP321 for Advanced Solid Tumors Clinical Trial.
Sign up to get notified when there's something new on the IMP321 for Advanced Solid Tumors Clinical Trial. page.

Latest updates to the IMP321 for Advanced Solid Tumors Clinical Trial. page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has updated its version from v2.14.4 to v2.15.0, indicating a significant revision. The phrase 'Here’s how you know' has been removed and replaced with a similar phrase.SummaryDifference1.0%
- Check31 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 13, 2025. However, the removal of the date March 25, 2025, does not significantly impact the core content.SummaryDifference1.0%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check81 days agoChange DetectedThe page has updated the date related to the feasibility and safety study of IMP321 (eftilagimod Alpha) for advanced stage solid tumors, changing it from November 7, 2024, to February 13, 2025.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
Stay in the know with updates to IMP321 for Advanced Solid Tumors Clinical Trial.
Enter your email address, and we'll notify you when there's something new on the IMP321 for Advanced Solid Tumors Clinical Trial. page.